Navigation Links
New drug target found for cystic fibrosis lung disease
Date:11/7/2012

Vancouver researchers have discovered the cellular pathway that causes lung-damaging inflammation in cystic fibrosis (CF), and that reducing the pathway's activity also decreases inflammation. The finding offers a potential new drug target for treating CF lung disease, which is a major cause of illness and death for people with CF.

"Developing new drugs that target lung inflammation would be a big step forward," says Dr. Stuart Turvey, who led the research. Dr. Turvey is the director of clinical research and senior clinician scientist at the Child & Family Research Institute and a pediatric immunologist at BC Children's Hospital. He is an associate professor in the Department of Pediatrics at the University of British Columbia.

The research was published online last week in the Journal of Immunology.

For the study, researchers compared the immune response of normal lung cells with that of CF lung cells after exposing both types of cells to bacteria in the lab. In healthy cells, exposure to bacteria triggers the cell to secrete special molecules that attract immune cells to fight the infection.

In CF lung cells, the researchers discovered that a series of molecular events called the unfolded protein response is more highly activated. It causes the CF lung cells to secrete more molecules that attract an excessive amount of immune cells, which leads to increased inflammation.

They also found that treating the CF cells with a special chemical normalized the unfolded protein response and stabilized the cells' immune response.

CF is the most common genetic disease affecting young Canadians. One in every 3600 children born in Canada has CF. There is no cure. A build-up of mucus in the lungs causes people with CF to be susceptible to bacterial lung infections, which trigger inflammation and swelling. Over time, the recurring cycle of infections and inflammation damages the lungs and can lead to the need for lung transplantation. The only treatments for lung inflammation are steroids and anti-inflammatory medications, which can have significant side effects.

The researchers are planning further study to validate these findings in a larger number of lung cell samples from people with CF.


'/>"/>
Contact: Jennifer Kohm
jkohm@cfri.ca
604-875-2401
Child & Family Research Institute
Source:Eurekalert

Related biology news :

1. LSUHSC research identifies new therapeutic target for Alzheimers disease
2. Single protein targeted as the root biological cause of several childhood psychiatric disorders
3. Research provides new insights into dogs natural feeding behavior and finds they target a daily dietary intake that is high in fat
4. Efforts to mitigate climate change must target energy efficiency
5. CU-Boulder researchers uncover new target for cancer research
6. New potential targets discovered for treating squamous cell lung cancers
7. Promising new drug target for inflammatory lung diseases
8. Scientists use worms to unearth cancer drug targets
9. Target for potent first-strike influenza drugs identified
10. Wayne State University researchers program targets safer river fishing, anglers health
11. New therapeutic target for prostate cancer identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... 2016 , ... Clinovo , the cloud-based eClinical software ... Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) Partner Program ... San Mateo, California on February 10th and 11th. Watch 2-min video . ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 /PRNewswire/ ... (PTP1B) Inhibitors-Pipeline Insights, 2016", report provides in ... their development activities around the Protein-Tyrosine Phosphatase ... the product profiles in various stages of ... Phase II, Phase III and Preregistration. Report ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016 Novan, Inc. today ... Chairman of the Board of Directors of Novan. In addition, ... North Carolina . --> ... Company also announced that it received a total of $32.8 million ... 2015 from its private investor network originating throughout the Research Triangle ...
Breaking Biology Technology: